Tucker Asset Management LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Tucker Asset Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 22.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,318 shares of the biopharmaceutical company’s stock after selling 1,838 shares during the period. Tucker Asset Management LLC’s holdings in Pfizer were worth $168,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PFE. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.8 %

PFE opened at $25.20 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $142.93 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The business has a fifty day simple moving average of $26.06 and a 200-day simple moving average of $26.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.